ArticleMolecular and cellular biochemistry2004
Role of proteases in the pathophysiology of cardiac disease.
Article in Molecular and cellular biochemistry, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Post-Ischemic Treatment of Recombinant Human Secretory Leukocyte Protease Inhibitor (rhSLPI) Reduced Myocardial Ischemia/Reperfusion Injury.Biomedicines · 2021Article
- Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.Biochemistry · 2020Article
- Functional selection of protease inhibitory antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Role of various proteases in cardiac remodeling and progression of heart failure.Heart failure reviews · 2012Review
- Detection of protease activities by flash chronopotentiometry using a reversible polycation-sensitive polymeric membrane electrode.Analytical biochemistry · 2011Article
- Tear me down: role of calpain in the development of cardiac ventricular hypertrophy.Circulation research · 2011Review
- Extracellular matrix roles during cardiac repair.Life sciences · 2010Review
- Lack of beta3 integrin signaling contributes to calpain-mediated myocardial cell loss in pressure-overloaded myocardium.Journal of cardiovascular pharmacology · 2010Article
- Development of inductively coupled plasma-mass spectrometry-based protease assays.Analytical biochemistry · 2010Article
- Calpain inhibition preserves myocardial structure and function following myocardial infarction.American journal of physiology. Heart and circulatory physiology · 2009Article
- Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function.Journal of cardiovascular pharmacology · 2009Article
- Calpain expression and activity during lens fiber cell differentiation.The Journal of biological chemistry · 2009Article
- Quantitative Measurement of Protease-Activity with Correction of Probe Delivery and Tissue Absorption Effects.Sensors and actuators. B, Chemical · 2009Article
- In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium.American journal of physiology. Heart and circulatory physiology · 2008Article
- Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs).Journal of cardiac failure · 2007Article
- Comprehensive survey of p94/calpain 3 substrates by comparative proteomics--possible regulation of protein synthesis by p94.Biotechnology journal · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is a major cause of death and thus a great deal of effort has been made in salvaging the diseased myocardium. Although various factors have been identified as possible causes of different cardiac diseases such as heart failure and ischemic heart disease, there is a real need to elucidate their role for the better understanding of the cardiac disease pathology and formulation of strategies for developing newer therapeutic interventions. In view of the intimate involvement of different types of proteases in maintaining cellular structure, the role of proteases in various cardiac diseases has become the focus of recent research. Proteases are present in the cytosol as well as are localized in a number of subcellular organelles in the cell. These are known to use extracellular matrix, cytoskeletal, sarcolemmal, sarcoplasmic reticular, mitochondrial and myofibrillar proteins as substrates. Work from different laboratories using a wide variety of techniques has shown that the activation of proteases causes alterations of a number of specific proteins leading to subcellular remodeling and cardiac dysfunction. Inhibition of protease action by different drugs and agents, therefore, has a clinical relevance and is expected to form a part of new treatment paradigm for improving heart function. This review examines the biochemistry and localization of some of the proteases in the cardiac tissue in addition to identification of the sites of action of some protease inhibitors. (Mol Cell Biochem 263: 241-256, 2004).
Indexed as
Identifiers
27520682What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.